doi: 10.1046/j.1365-2141.2002.03429.x.
FGFR3 dysregulation in multiple myeloma: frequency and prognostic relevance
Affiliations
- PMID: 12028033
- DOI: 10.1046/j.1365-2141.2002.03429.x
Item in Clipboard
FGFR3 dysregulation in multiple myeloma: frequency and prognostic relevance
Br J Haematol.
2002 Jun.
Abstract
The t(4:14) translocation affects two potential oncogenes, FGFR3 and MMSET, in multiple myeloma (MM). We investigated the frequency of FGFR3 dysregulation and its prognostic value in MM. FGFR3 mRNA levels were determined in 110 diagnostic bone marrow (BM) samples from MM patients. In addition, selected BM samples were screened for elevated MMSET mRNA levels. 14.5% (16/110) of MM BM samples showed dysregulated FGFR3 expression. Follow-up of 76 MM patients showed no significant difference between FGFR3 dysfunction and survival (P = 0.3) or correlation with known prognostic factors. Further, no linear relation was observed between FGFR3 and MMSET levels.
Comment in
-
t(4;14)(p16.3;q32) is strongly associated with a shorter survival in myeloma patients.Br J Haematol. 2003 Jan;120(1):170-1. doi: 10.1046/j.1365-2141.2003.03983_5.x. Br J Haematol. 2003. PMID: 12492597 No abstract available.
Similar articles
-
The t(4;14) translocation in myeloma dysregulates both FGFR3 and a novel gene, MMSET, resulting in IgH/MMSET hybrid transcripts.Blood. 1998 Nov 1;92(9):3025-34. Blood. 1998. PMID: 9787135
-
A molecular study of the t(4;14) in multiple myeloma.Br J Haematol. 2002 Aug;118(2):514-20. doi: 10.1046/j.1365-2141.2002.03618.x. Br J Haematol. 2002. PMID: 12139740
-
Expression of fibroblast growth factor and FGF-receptor family genes in human myeloma cells, including lines possessing t(4;14)(q16.3;q32. 3) and FGFR3 translocation.Int J Oncol. 1999 Dec;15(6):1205-12. doi: 10.3892/ijo.15.6.1205. Int J Oncol. 1999. PMID: 10568829
-
The enigma of ectopic expression of FGFR3 in multiple myeloma: a critical initiating event or just a target for mutational activation during tumor progression.Curr Opin Hematol. 2002 Jul;9(4):288-93. doi: 10.1097/00062752-200207000-00005. Curr Opin Hematol. 2002. PMID: 12042702 Review.
-
MMSET: role and therapeutic opportunities in multiple myeloma.Biomed Res Int. 2014;2014:636514. doi: 10.1155/2014/636514. Epub 2014 Jul 1. Biomed Res Int. 2014. PMID: 25093175 Free PMC article. Review.
Cited by
-
[Clinical characteristics and prognosis of newly diagnosed multiple myeloma patients with FGFR3 gene mutations].Zhonghua Xue Ye Xue Za Zhi. 2023 Dec 14;44(12):989-994. doi: 10.3760/cma.j.issn.0253-2727.2023.12.004. Zhonghua Xue Ye Xue Za Zhi. 2023. PMID: 38503521 Free PMC article. Chinese.
-
Genome wide transcriptional profiling in breast cancer cells reveals distinct changes in hormone receptor target genes and chromatin modifying enzymes after proteasome inhibition.Mol Carcinog. 2008 Nov;47(11):845-85. doi: 10.1002/mc.20440. Mol Carcinog. 2008. PMID: 18381591 Free PMC article.
-
FGF signaling inhibits the proliferation of human myeloma cells and reduces c-myc expression.BMC Cell Biol. 2003 Dec 4;4:17. doi: 10.1186/1471-2121-4-17. BMC Cell Biol. 2003. PMID: 14656381 Free PMC article.
-
Survival and proliferation factors of normal and malignant plasma cells.Int J Hematol. 2003 Aug;78(2):106-13. doi: 10.1007/BF02983377. Int J Hematol. 2003. PMID: 12953803 Free PMC article. Review.
-
Association of Chromosomal Translocation and MiRNA Expression with The Pathogenesis of Multiple Myeloma.Cell J. 2014 Summer;16(2):99-110. Epub 2014 May 25. Cell J. 2014. PMID: 24567933 Free PMC article. Review.
Publication types
MeSH terms
Substances
LinkOut - more resources
Full Text Sources
Other Literature Sources
Medical
